NDAORALCAPSULE
Approved
Jul 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NAVANE (thiothixene) is an oral antipsychotic capsule approved in 1967 for the treatment of schizophrenia. The drug's mechanism of action is not fully characterized in available data, but it represents a first-generation antipsychotic class. It is administered orally and remains a legacy treatment option in the schizophrenia market.
LOE Approaching
As a legacy asset approaching loss of exclusivity, NAVANE brand team sizes are likely minimal with focus on cost management and market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NAVANE offers limited career growth opportunities due to its LOE-approaching status and minimal linked job postings. Roles focus on defensive commercial strategy, cost management, and regulatory compliance rather than high-impact innovation or expansion.
Brand ManagerField Sales Representative
Worked on NAVANE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.